RARECast: Sobi Works to Expand Rare Disease Indications for Its Drugs

January 27, 2017

Sobi is a drugmaker focused on hemophilia, inflammation, and genetic and metabolic diseases. It is now pursuing its drug Orfadin, used to treat the metabolic disorder Tyrosemia Type 1, as a potential treatment for the metabolic condition Alkaptonuria. It is also pursuing Kineret, a drug for the rare inflammatory condition NOMID, as a potential therapy for Still’s Disease. We spoke to Rami Levin, President of North America for Sobi, and Len Walt, VP & Head of Medical Affairs of North America for Sobi, about the company’s evolution, its growing pipeline, and its effort to expand indications for its rare disease drugs.
RARECast is a weekly series by Daniel S. Levine. Levine is an award-winning business journalist who has reported on the life sciences, economic development, and business policy issues throughout his 25-year career. He founded Levine Media Group in 2013, which produces The Bio Report and RARECast podcasts. Read his full bio here. 

Stay Connected

Sign up for updates straight to your inbox.